SIRNA AGAINST CBL-B COMBINED WITH CYTOKINES AND INTERFERONS IN THE TREATMENT OF CANCER

Use of Cbl-b inhibitor in a method of therapeutic treatment of a patient comprising the introduction of the Cbl-b inhibitor in natural killer (NK) cells of the patient, is claimed, where the NK cells are immune activated. Independent claims are included for: (1) immune activation of NK cells, compri...

Full description

Saved in:
Bibliographic Details
Main Authors SCHUSTER, Manfred, HASLINGER, Isabella, SEIDL, Sandra, LOIBNER, Hans, LAMETSCHWANDTNER, Günther
Format Patent
LanguageEnglish
French
German
Published 25.01.2017
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Use of Cbl-b inhibitor in a method of therapeutic treatment of a patient comprising the introduction of the Cbl-b inhibitor in natural killer (NK) cells of the patient, is claimed, where the NK cells are immune activated. Independent claims are included for: (1) immune activation of NK cells, comprising reducing or inhibiting the Cbl-b function in the NK-cells, preferably by administration of the Cbl-b inhibitor; and (2) a pharmaceutical composition comprising the Cbl-b inhibitor, and an additional NK cell activator. ACTIVITY : Cytostatic; Antimicrobial; Antiparasitic. MECHANISM OF ACTION : Cbl-b expression inhibitor; E3 ligase inhibitor.
Bibliography:Application Number: EP20110805055